دورية أكاديمية
Utility of iliac crest tetracycline-labelled bone biopsy in osteoporosis and metabolic bone disease: An evaluation of 95 cases over a period of 25 years.
العنوان: | Utility of iliac crest tetracycline-labelled bone biopsy in osteoporosis and metabolic bone disease: An evaluation of 95 cases over a period of 25 years. |
---|---|
المؤلفون: | Colazo JM; Medical Scientist Training Program, Vanderbilt University School of Medicine, Nashville, TN, USA., Quirion J; Division of Musculoskeletal Oncology, Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA., Judice AD; Division of Musculoskeletal Oncology, Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA., Halpern J; Division of Musculoskeletal Oncology, Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA., Schwartz HS; Division of Musculoskeletal Oncology, Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA., Tanner SB; Department of Medicine, Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Lawrenz JM; Division of Musculoskeletal Oncology, Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA., Dahir KM; Department of Medicine, Division of Endocrinology and Diabetes, Vanderbilt University Medical Center, Nashville, TN, USA., Holt GE; Division of Musculoskeletal Oncology, Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA. |
المصدر: | Bone reports [Bone Rep] 2023 Sep 24; Vol. 19, pp. 101715. Date of Electronic Publication: 2023 Sep 24 (Print Publication: 2023). |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101646176 Publication Model: eCollection Cited Medium: Print ISSN: 2352-1872 (Print) Linking ISSN: 23521872 NLM ISO Abbreviation: Bone Rep Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: [Philadelphia] : Elsevier Inc., [2015]- |
مستخلص: | Background: Metabolic bone diseases (MBD) are typically diagnosed by non-invasive imaging and clinical biomarkers. However, imaging does not provide structural information, and biomarkers can be transiently affected by many systemic factors. Bone biopsy and pathologic evaluation is the gold standard for diagnosis of MBD, however, it is rarely utilized. We describe our technique for iliac crest tetracycline-labelled bone using a cannulated drill and assess the utility of bone biopsies to provide diagnostic and therapeutic guidance. Methods: In the 25-year period between March 1998 and January 2023, a total of 95 bone biopsies were performed on 94 patients for an osteological indication at Vanderbilt University Medical Center (VUMC). Patient demographics, bone biopsy indications, complications, diagnostic utility, and subsequent therapeutic guidance were retrospectively reviewed and analyzed. Results: The procedure had minimal complications and was well tolerated by patients. This technique provided good quality specimens for pathology, which helped establish a diagnosis and treatment change in most patients. Patients that had biopsy-guided treatment alterations showed significant increases in Dual-Energy X-ray Absorptiometry (DEXA) bone mineral density (BMD) scores post-biopsy and subsequent treatment. Conclusion: Despite scientific and technological progress in non-invasive diagnostic imaging, clinical biomarkers, and procedures for MBD, there remains a small but significant subset of patients who may benefit from inclusion of tetracycline-labelled bone biopsy into the diagnostic and therapeutic picture. Future prospective comparison studies are warranted. Mini Abstract: Tetracycline-labelled bone biopsies are under-utilized. Biopsy led to a histological diagnosis and ensuing treatment alteration in most patients with significant increases in bone mineral density. The biopsy procedure used herein provided good specimens with low pain/adverse events. Bone biopsy remains a valuable tool in a small, though significant, subset of patients. Competing Interests: Juan M. Colazo, Julia Quirion, Anthony D. Judice, Jennifer Halpern, Herbert S. Schwartz, S. Bobo Tanner, Kathryn M. Dahir, Joshua M. Lawrenz, and Ginger E. Holt declare that they have no conflict of interest. (© 2023 The Authors.) |
References: | J Clin Endocrinol Metab. 2005 Mar;90(3):1294-301. (PMID: 15598694) Reumatismo. 2004 Jan-Mar;56(1):15-23. (PMID: 15105905) World J Mens Health. 2021 Oct;39(4):750-759. (PMID: 33474849) J Clin Densitom. 2004 Spring;7(1):27-36. (PMID: 14742885) Bone Rep. 2018 Mar 17;8:125-134. (PMID: 29955631) J Bone Miner Metab. 2022 Jul;40(4):613-622. (PMID: 35333984) Am J Kidney Dis. 2016 Apr;67(4):559-66. (PMID: 26321176) J Bone Joint Surg Am. 1983 Dec;65(9):1314-8. (PMID: 6361037) Endocr Rev. 2002 Aug;23(4):517-23. (PMID: 12202466) Calcif Tissue Res. 1969;3(3):211-37. (PMID: 4894738) Pediatr Nephrol. 2000 Jul;14(7):629-35. (PMID: 10912532) Per Med. 2010 Nov;7(6):655-668. (PMID: 29788568) J Clin Med. 2021 Oct 08;10(19):. (PMID: 34640633) J Bone Miner Res. 2001 Oct;16(10):1846-53. (PMID: 11585349) Curr Osteoporos Rep. 2016 Aug;14(4):138-50. (PMID: 27263108) J Nephrol. 2016 Oct;29(5):617-26. (PMID: 27473148) Pharmgenomics Pers Med. 2009;2:69-78. (PMID: 23226036) Case Rep Endocrinol. 2020 Jul 9;2020:1047327. (PMID: 32695531) Virchows Arch A Pathol Anat Histopathol. 1991;418(1):1-7. (PMID: 1899163) PLoS One. 2022 Jul 19;17(7):e0271555. (PMID: 35853025) J Clin Endocrinol Metab. 2008 Oct;93(10):3785-93. (PMID: 18682511) Clin Orthop Relat Res. 1969 Jul-Aug;65:203-17. (PMID: 5802527) Bone. 2018 Nov;116:215-220. (PMID: 30098418) Pathol Biol. 1964 Dec;12:1238-43. (PMID: 14255816) Clin Chem. 2017 Feb;63(2):464-474. (PMID: 27940448) Eur J Rheumatol. 2017 Mar;4(1):46-56. (PMID: 28293453) Arch Pathol. 1969 Nov;88(5):508-10. (PMID: 5347140) J Bone Miner Res. 2004 May;19(5):745-51. (PMID: 15068497) OMICS. 2012 Dec;16(12):638-51. (PMID: 23215803) Curr Osteoporos Rep. 2007 Dec;5(4):146-52. (PMID: 18430388) Osteoporos Int. 2006;17(11):1653-8. (PMID: 16871433) J Bone Miner Res. 2004 Aug;19(8):1250-8. (PMID: 15231011) PLoS One. 2014 Feb 13;9(2):e88946. (PMID: 24551194) Geriatr Gerontol Int. 2016 Mar;16 Suppl 1:57-65. (PMID: 27018284) Korean J Intern Med. 1988 Jul;3(2):132-5. (PMID: 3154190) Semin Arthritis Rheum. 2015 Apr;44(5):477-482. (PMID: 25312241) J Bone Miner Res. 2016 Aug;31(8):1527-35. (PMID: 26931279) Can Assoc Radiol J. 2021 Aug;72(3):490-504. (PMID: 32309998) J Bone Miner Res. 2014 Mar;29(3):618-28. (PMID: 23959630) Clin Rheumatol. 2006 Feb;25(1):30-4. (PMID: 15915321) J Clin Endocrinol Metab. 2016 Apr;101(4):1353-63. (PMID: 26859106) Scand J Haematol. 1971;8(1):69-71. (PMID: 5566975) |
فهرسة مساهمة: | Keywords: Antibiotic-labelled bone biopsy; Bone biopsy; Metabolic bone disease; Osteomalacia; Osteoporosis; Tetracycline labelling |
تواريخ الأحداث: | Date Created: 20231009 Latest Revision: 20231030 |
رمز التحديث: | 20231031 |
مُعرف محوري في PubMed: | PMC10558706 |
DOI: | 10.1016/j.bonr.2023.101715 |
PMID: | 37811524 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!